Home › Trials › NCT03594760
Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up Men only

Using PSMA-PET imaging to predict prostate cancer progression and treatment response

Official title: PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Run by Centre hospitalier de l'Université de Montréal (CHUM) · NCT03594760 · Data updated 2026-11-12

This study is testing a new imaging method called PSMA-PET to see if it can better detect advanced prostate cancer and help doctors make better treatment decisions for patients.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment1000 (estimated)
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
Academic / other
Locations1 site (Montreal, Quebec)
StatusRecruiting
StartedDecember 1, 2018
Main results expectedDecember 2028
Study endsDecember 2029
Registry record updatedMarch 19, 2026
Trial IDNCT03594760 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with prostate cancer who are being treated at CHUM and have a physician's request for a PSMA-PET scan.

Probably not a fit

Patients who are claustrophobic or unable to complete the imaging procedure will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial focuses on utilizing a novel imaging technique called PSMA-PET to assess metastatic prostate cancer in patients. By injecting a tracer (18F-DCFPyL), the study aims to evaluate the effectiveness of this imaging method in detecting metastases more accurately than traditional imaging techniques. The goal is to map the metastatic state of prostate cancer to better guide treatment decisions and improve patient outcomes. The trial will involve patients being treated at the Centre hospitalier de l'Université de Montréal who require a PSMA-PET scan as part of their care.

Why it matters

Potential benefit: If successful, this study could lead to more accurate treatment planning and improved outcomes for patients with metastatic prostate cancer.

How similar studies have gone: Other studies have shown promising results with PSMA-PET imaging, indicating its potential effectiveness in clinical settings.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients with prostate cancer, being followed and treated at CHUM, whose treating physician at CHUM has requested a PSMA-PET scan.

Exclusion Criteria:

* Claustrophobia/inability to complete imaging procedure.

Where it's running

  • Centre Hospitalier de l'université de Montréal
    Montreal, Quebec, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Centre hospitalier de l'Université de Montréal (CHUM) 72
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.